On May 18, the FTC announced a settlement with a company that offered cognitive training at its LearningRx centers.  The FTC alleged that the company promoted its training programs with claims to raise IQ and therefore raise income; improve performance in school and on standardized tests; improve athletic performance through improved cognition; and treat serious diseases and conditions, including Attention Deficit Disorder, autism, dementia, Alzheimer’s disease, and traumatic brain injury.

The company and an individual officer agreed to pay $200,000 in redress.  Four million dollars ($4,000,000) will become due if it is later found that they misrepresented their financial status.  Under the settlement order, they must also possess well-controlled clinical testing for any similar brain or cognitive function claims made in the future.

This new settlement shows that the FTC continues to focus heavily on claims to improve cognitive function.  Since 2014, the FTC has taken action against cognitive function claims in five cases.  From 2000 until 2013, it brought only one action on cognitive function claims.